ReP USP - Resultado da busca

Artigo de periodico
Humoral and cellular immune responses to CoronaVac up to one year after vaccination (2022)
Costa, Priscilla Ramos; Correia, Carolina Argondizo ; Marmorato, Mariana Prado ; Dias, Juliana Zanatta de Carvalho; Thomazella, Mateus Vailant ; Silva, Amanda Cabral da; Oliveira, Ana Carolina Soares de; Gusmao, Arianne Fagotti; Ferrari, Lilian; Freitas, Angela Carvalho ; Kallas, Esper Georges
Source: Frontiers in immunology. Unidade: FM
Subjects: COVID-19, VACINAS VIRAIS, SISTEMA IMUNE, CITOCINAS, ANTÍGENOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Priscilla Ramos et al. Humoral and cellular immune responses to CoronaVac up to one year after vaccination. Frontiers in immunology, v. 13, 2022Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/50534. Acesso em: 09 nov. 2024.
APA
Costa, P. R., Correia, C. A., Marmorato, M. P., Dias, J. Z. de C., Thomazella, M. V., Silva, A. C. da, et al. (2022). Humoral and cellular immune responses to CoronaVac up to one year after vaccination. Frontiers in immunology, 13. doi:10.3389/fimmu.2022.1032411
NLM
Costa PR, Correia CA, Marmorato MP, Dias JZ de C, Thomazella MV, Silva AC da, Oliveira ACS de, Gusmao AF, Ferrari L, Freitas AC, Kallas EG. Humoral and cellular immune responses to CoronaVac up to one year after vaccination [Internet]. Frontiers in immunology. 2022 ; 13[citado 2024 nov. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50534
Vancouver
Costa PR, Correia CA, Marmorato MP, Dias JZ de C, Thomazella MV, Silva AC da, Oliveira ACS de, Gusmao AF, Ferrari L, Freitas AC, Kallas EG. Humoral and cellular immune responses to CoronaVac up to one year after vaccination [Internet]. Frontiers in immunology. 2022 ; 13[citado 2024 nov. 09 ] Available from: https://observatorio.fm.usp.br/handle/OPI/50534
Artigo de periodico
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial (2020)
Kallás, Esper Georges ; Precioso, Alexander Roberto; Palacios, Ricardo; Thome, Beatriz; Braga, Patricia Emilia; Vanni, Tazio; Campos, Lucia M. A; Ferrari, Lilian; Mondini, Gabriella; Kalil Filho, Jorge Elias
Source: Lancet infectious diseases. Unidade: FM
Subjects: ANTICORPOS, IMUNOGENICIDADE DA VACINA, MÉTODO DUPLO-CEGO, VÍRUS DA DENGUE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KALLÁS, Esper Georges et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, v. 20, n. 7, p. 839-850, 2020Tradução . . Disponível em: https://doi.org/10.1016/S1473-3099(20)30023-2. Acesso em: 09 nov. 2024.
APA
Kallás, E. G., Precioso, A. R., Palacios, R., Thome, B., Braga, P. E., Vanni, T., et al. (2020). Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet infectious diseases, 20( 7), 839-850. doi:10.1016/S1473-3099(20)30023-2
NLM
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2
Vancouver
Kallás EG, Precioso AR, Palacios R, Thome B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, Kalil Filho JE. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial [Internet]. Lancet infectious diseases. 2020 ; 20( 7): 839-850.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1016/S1473-3099(20)30023-2
Artigo de periodico-carta/editorial
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial (2020)
Palacios, Ricardo; Patino, Elizabeth Gonzalez; Piorelli, Roberta de Oliveira; Conde, Monica Tilli Reis Pessoa; Batista, Ana Paula; Zeng, Gang; Xin, Qianqian; Kallas, Esper Georges ; Flores, Jorge; Ockenhouse, Christian F
Source: Trials. Unidade: FM
Subjects: COVID-19, PANDEMIAS, VACINAS, VACINAÇÃO, ENVELHECIMENTO, INCIDÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PALACIOS, Ricardo et al. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial. Trials. London: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1186/s13063-020-04775-4. Acesso em: 09 nov. 2024. , 2020
APA
Palacios, R., Patino, E. G., Piorelli, R. de O., Conde, M. T. R. P., Batista, A. P., Zeng, G., et al. (2020). Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial. Trials. London: Faculdade de Medicina, Universidade de São Paulo. doi:10.1186/s13063-020-04775-4
NLM
Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial [Internet]. Trials. 2020 ; 21( 1):[citado 2024 nov. 09 ] Available from: https://doi.org/10.1186/s13063-020-04775-4
Vancouver
Palacios R, Patino EG, Piorelli R de O, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV . [Carta]: a structured summary of a study protocol for a randomised controlled trial [Internet]. Trials. 2020 ; 21( 1):[citado 2024 nov. 09 ] Available from: https://doi.org/10.1186/s13063-020-04775-4

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies